Furthermore, we indicated that SLCO4A1-AS1 promotes GC proliferation and metastasis by sponging miR-149 to promote XIAP expression, suggesting that SLCO4A1-AS1 functions as a novel prognostic biomarker and a potential antimetastatic therapeutic target for the treatment of GC. Here, XIAP is linked to gastric cancer.